Trends in hospitalizations of children with respiratory syncytial virus aged less than 1 year in Italy, from 2015 to 2019
Authors:
- Renato CutreraRCRenato Cutrera
- Daniela D’aNgelaDDDaniela D’aNgela
- Massimiliano OrsoMOMassimiliano Orso
- Liliana GuadagniLGLiliana Guadagni
- Anna Chiara VittucciAVAnna Chiara Vittucci
- Barbara PolistenaBPBarbara Polistena
- Federico SpandonaroFSFederico Spandonaro
- Ciro CarrieriCCCiro Carrieri
- Eva Agostina MontuoriEMEva Agostina Montuori
- Raffaella IantomasiRIRaffaella Iantomasi
Open Access
- 21 June 2024
- journal article
- research article
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 50 (1) , 1-7
Abstract
Background: Respiratory syncytial virus (RSV) affects 60–80% of children below 1 year and it’s the first cause of acute bronchiolitis. The aim of this study was to assess the trend and characteristics of hospitalizations for RSV infections in Italy. Methods: This is a retrospective study based on the Italian Hospital Discharge Record (HDR) database. We analysed HDRs from June 2015 to May 2019, considering two groups of infants: Group 1 had a confirmed diagnosis of RSV; Group 2 had a diagnosis of acute bronchiolitis not RSV-coded. Results: There were 67,746 overall hospitalizations (40.1% Group 1, and 59.9% Group 2). Hospitalization rate increased for Group 1 from 125 to 178 per 10,000 infants (+ 42.4%), and for Group 2 from 210 to 234 per 10,000 (+ 11.4%). The mean hospitalization length was 6.3 days in Group 1, longer than Group 2 (+ 1.0 day). A further analysis revealed that infants with heart disease or born premature had longer mean hospital stay compared to infants without risk factors (10.7 days versus 6.1 days, p < 0.0001; 34.0 days versus 6.1 days, p < 0.0001, respectively). Group 1 required more critical care (oxygen therapy and/or mechanical ventilation) than Group 2. We found that, in proportion to hospital admissions in pediatric and general hospitals, RSV was more frequently diagnosed in the first ones. The mean hospitalization cost increased for Group 1 (from € 2,483 to € 2,617) and Group 2 (from € 2,007 to € 2,180). Conclusions: Our results confirmed that RSV pulmonary disease in infants is seasonal and often requires hospitalization. Our study suggested that RSV is responsible for an increasing hospitalization rate and related costs during the study period.Keywords
Funding Information
- Pfizer Italia (Pfizer Italia)
This publication has 16 references indexed in Scilit:
- Human respiratory syncytial virus and hospitalization in young children in ItalyItalian Journal of Pediatrics, 2018
- Respiratory syncytial virus seasonality and its implications on prevention strategiesHuman Vaccines & Immunotherapeutics, 2017
- Respiratory syncytial virus hospitalization and mortality: Systematic review and meta‐analysisPediatric Pulmonology, 2016
- Modelling estimates of the burden of respiratory syncytial virus infection in children in the UKBMJ Open, 2016
- Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeuticsThe Lancet Respiratory Medicine, 2015
- The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) StatementPLOS Medicine, 2015
- Incidence, risk factors and hospital burden in children under five years of age hospitalised with respiratory syncytial virus infectionsActa Paediatrica, 2015
- Acute bronchiolitis in infants, a reviewScandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2014
- Risk Factors for Hospital Admission with RSV Bronchiolitis in England: A Population-Based Birth Cohort StudyPLOS ONE, 2014
- Respiratory Syncytial Virus—A Comprehensive ReviewClinical Reviews in Allergy & Immunology, 2013